Falling Asleep During Activities of Daily Living has been reported during the treatment with Ronirol. Read the Warning Section below
Ronirol (ropinirole hydrochloride) is a non-ergoline dopamine agonist.
Presentation
- Ronirol 0.25mg film coated tablets
- Ronirol 1 mg film coated tablets
- Ronirol 2 mg film coated tablets
Mechanism of Action
Ronirol (ropinirole) is a non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. Ronirol (ropinirole) has moderate in vitro affinity for opioid receptors. Ronirol (ropinirole) and its metabolites have negligible in vitro affinity for dopamine D1, 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, alpha1, alpha24 and beta- adrenoreceptors.
Indications
Parkinson’s Disease
for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.
Restless Legs Syndrome
for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Contraindications
Ronirol (ropinirole) is contraindicated for patients known to have hypersensitivity to the product.
Warnings
Patients treated with Ronirol (ropinirole) have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Although many of these patients reported somnolence while on Ronirol (ropinirole), some perceived that they had no warning signs such as excessive drowsiness, and believed that they were alert immediately prior to the event. Some of these events have been reported as late as 1 year after initiation of treatment.
